Julius Knowles, Director at Keros Therapeutics, Inc. (KROS), sold 53,332 shares at $47.69 ($2.6M) on 2021-06-03, disclosed to the SEC on 2021-06-03.
Open-market sale of $2.6M KROS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $51.90 | 1,504 | $78K | 3.0% |
| 2 | $51.90 | 2,309 | $120K | 4.5% |
| 3 | $51.90 | 2,309 | $120K | 4.5% |
| 4 | $51.90 | 1,504 | $78K | 3.0% |
| 5 | $52.72 | 2,345 | $124K | 4.7% |
| 6 | $52.72 | 1,531 |
| $81K |
| 3.1% |
| 7 | $52.72 | 1,531 | $81K | 3.1% |
| 8 | $52.72 | 2,345 | $124K | 4.7% |
| 9 | $53.77 | 633 | $34K | 1.3% |
| 10 | $53.77 | 414 | $22K | 0.8% |
| 11 | $54.62 | 46 | $3K | 0.1% |
| 12 | $54.62 | 30 | $2K | 0.1% |
| 13 | $48.35 | 3,225 | $156K | 5.9% |
| 14 | $48.35 | 3,225 | $156K | 5.9% |
| 15 | $48.35 | 4,944 | $239K | 9.0% |
| 16 | $48.35 | 4,944 | $239K | 9.0% |
| 17 | $49.26 | 874 | $43K | 1.6% |
| 18 | $49.26 | 1,343 | $66K | 2.5% |
| 19 | $49.26 | 1,343 | $66K | 2.5% |
| 20 | $50.52 | 553 | $28K | 1.1% |
| 21 | $50.52 | 361 | $18K | 0.7% |
| 22 | $51.45 | 138 | $7K | 0.3% |
| 23 | $51.45 | 91 | $5K | 0.2% |
| 24 | $47.69 | 1,213 | $58K | 2.2% |
| 25 | $47.69 | 1,213 | $58K | 2.2% |
| 26 | $47.69 | 1,862 | $89K | 3.4% |
| 27 | $47.69 | 1,862 | $89K | 3.4% |
| 28 | $48.15 | 1,903 | $92K | 3.5% |
| 29 | $48.15 | 1,903 | $92K | 3.5% |
| 30 | $48.15 | 2,917 | $140K | 5.3% |
| 31 | $48.15 | 2,917 | $140K | 5.3% |
| Total | $49.61 avg | 53,332 | $2.6M | 100% |
| Filing → |
| KROS | SELL | 2022-01-05 | $5.3M | — | Filing → |
| KROS | SELL | 2021-12-03 | $5.1M | — | Filing → |
| KROS | SELL | 2021-11-03 | $3.9M | — | Filing → |